Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
In the COVID-19 pandemic era, a convenient and effective treatment for pediatric patients is
unavailable. A multi-center Chinese clinical trials with the aim to using Interferon-α2b
spray inhalation to develop new treatment strategies for the treatment of pediatric patients
with mild or moderate type of COVID-19. The purpose of this study is to determine the safety
and efficacy for Interferon α2b spray inhalation as first line treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Children's Hospital of Fudan University
Collaborators:
RenJi Hospital Shanghai Children's Hospital Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine